

<2022 J.P. Morgan Healthcare Conference Speech Key Take-aways>

About Seegene

- Seegene was established in 2000 with the mission of the global adoption of molecular diagnostic to daily lives. With our global network, 8 subsidiaries and approximately 100 agencies globally, Seegene showed an unprecedented growth in 2020 and recorded 9-fold and 33-fold YoY surge in revenue and operating profit, respectively.
- Amid emergence of continuously mutating COVID-19 viruses, Seegene has responded agilely via development of assays including the assays that simultaneously identify various variants of COVID-19 and the syndromic assay that screens multiple pathogens related to common respiratory symptoms.

Three Solutions for back to normal'

- Seegene addressed three strategic solutions that could help streamline the 'back to normal' campaign. Solution 1: on-site MDx screening is available with mass testing capability. High throughput PCR testing with short turn-around-time (TAT) was not practically available until now. Seegene's onsite screening solution enables rapid and mass MDx testing with the same cost and TAT as antigen tests. The on-site MDx screening solution can even detect asymptomatic infections which rapid antigen tests easily slip through and produce false-negative cases.
- Solution 2: Seegene's centralized screening solution can at least double the test capacity using existing PCR and liquid handler instruments in all test laboratories, substantially increasing the maximum testing volume without any additional investment.
- Solution 3: Seegene's syndromic testing solution is available for patients presenting the common respiratory symptoms. Allplex™ RV Master Assay simultaneously tests for 10 different targets including COVID-19, Flu, and common respiratory viruses.

Concept of Seegene MDx Platform

- Seegene also unveiled blueprint for the future of molecular diagnostics as the company introduces the digitalized open development platform, SDGGS. The standard development tool is the key to create an environment where anyone can easily develop a syndromic assay. Seegene will provide grant and high-multiplex assay development tools, as well as standard raw materials and development instruments.

- Through Seegene Intelligence, the MDx platform in which anyone could have access to develop syndromic assays, seegene's product line-up will continuously expand to cover human and non-human fields.
- After all, with 'One System', which allows single set of instruments to conduct all types of existing syndromic assays, Seegene continuously helps the clinical laboratory to set the idealistic testing environment. Seegene will develop diverse One Systems from the low throughput POC to high throughput full-automation.